DaVita Inc. (DVA) stock analysis

Healthcare · Medical Care Facilities

From the 10-K filed 2026-02-11

Business type: Franchise

How it makes money

DaVita earns revenue by providing outpatient dialysis and kidney care, with overall profits depending heavily on higher-paying commercial payor plans.

DaVita operates primary lines of business centered on kidney disease care, with its largest segment being U.S. dialysis and related lab services for end stage renal disease patients. It also operates international dialysis centers and an integrated kidney care business.

Patients with end stage renal disease require regular artificial filtration treatments to survive. While government programs cover many patients, overall profit performance is driven by the proportion of patients covered by higher-paying commercial insurance plans.

What protects it: the moat

Management relies on established nephrology and payor relationships alongside a large operational platform to defend its position in kidney care.

DaVita maintains its market position through an established platform of outpatient centers and relationships with nephrologists and commercial payors.

The filing asserts competitive strengths from its scale and care delivery network, but does not provide quantitative competitive metrics, making these advantages management's claim.

What growth costs

Maintaining and expanding operations requires investments in labor, outpatient centers, international expansion, and integrated care arrangements.

Operating dialysis services requires substantial ongoing labor and clinical facility infrastructure across outpatient centers. The business is labor-intensive, making ongoing workforce recruitment and retention essential to keep existing clinics functioning.

To expand, the company invests in international operations, which provided dialysis and administrative services to 585 outpatient dialysis centers across 14 countries serving approximately 94,500 patients outside the U.S. It also invests in integrated kidney care arrangements, providing services to 66,000 patients in risk-based models.

What could damage it

Downward pricing pressure or shift of patients away from commercial payor plans directly reduces profitability across dialysis operations.

DaVita's profitability depends heavily on reimbursement rates from commercial insurance payors, which pay significantly higher rates than government programs.

If commercial payors successfully push down realized reimbursement rates or if restrictive plan designs shift patients away from commercial coverage, the business suffers direct margin erosion that cannot be offset by government-funded treatments.

About DaVita Inc.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

More on DVA

Other companies in Medical Care Facilities